Heim22UA • FRA
add
BioNTech SE - ADR
Við síðustu lokun
82,30 €
Dagbil
82,05 € - 87,50 €
Árabil
69,70 € - 124,60 €
Markaðsvirði
22,27 ma. USD
Meðalmagn
1,56 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Stock Titan
fyrir 2 dögum
BioNTech Taps Novartis Executive to Drive Oncology Transformation as New CFO
1,18%
2,05%
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (EUR) | mar. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 182,80 m. | -2,56% |
Rekstrarkostnaður | 593,40 m. | -6,05% |
Nettótekjur | -415,80 m. | -31,96% |
Hagnaðarhlutfall | -227,46 | -35,43% |
Hagnaður á hvern hlut | -1,73 | -32,06% |
EBITDA | -451,60 m. | 2,84% |
Virkt skatthlutfall | 6,65% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (EUR) | mar. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 14,11 ma. | -9,94% |
Heildareignir | 21,18 ma. | -4,83% |
Heildarskuldir | 2,26 ma. | -1,43% |
Eigið fé alls | 18,93 ma. | — |
Útistandandi hlutabréf | 240,39 m. | — |
Eiginfjárgengi | 1,05 | — |
Arðsemi eigna | -5,65% | — |
Ávöxtun eigin fjár | -6,36% | — |
Peningaflæði
Breyting á handbæru fé
| (EUR) | mar. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -415,80 m. | -31,96% |
Handbært fé frá rekstri | -780,70 m. | -146,04% |
Reiðufé frá fjárfestingum | 1,25 ma. | 154,11% |
Reiðufé frá fjármögnun | -13,80 m. | -76,92% |
Breyting á handbæru fé | 423,00 m. | 115,74% |
Frjálst peningaflæði | -1,37 ma. | -175,36% |
Um
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Framkvæmdastjóri
Stofnsett
2008
Vefsvæði
Starfsfólk
6.772
